nach oben

Quality of Life Research

Erschienen in:

16.06.2018

Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

verfasst von: N. E. Carlozzi, S. Schilling, A. L. Kratz, J. S. Paulsen, S. Frank, J. C. Stout

Erschienen in: Quality of Life Research | Ausgabe 10/2018

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Purpose

Symptom progression in Huntington disease (HD) is associated with cognitive decline which may interfere with the self-report of symptoms. Unfortunately, data to support or refute the psychometric reliability of patient-reported outcomes (PROs) as HD progresses are limited. This is problematic given that PROs are increasingly recognized as important measures of efficacy for new treatments.

Methods

We examined PRO data from the HDQLIFE Measurement System (Speech Difficulties; Swallowing Difficulties; Chorea) in 509 individuals with premanifest, early-stage, or late-stage HD. Clinician-administered assessments of motor functioning (items from the UHDRS) and standardized objective assessments of cognition (Stroop, Symbol Digit Modalities) were also collected. We examined item bias using differential item functioning (DIF) across HD stage (premanifest, early-, late-) and relative to cognitive performance. We also examined the correlations between self-report and clinician ratings. Regression models that considered total cognitive ability were utilized to determine psychometric reliability of the PROs.

Results

Most PRO items were free from DIF for both staging and cognition. There were modest correlations between PROs and clinician report (ranged from − 0.40 to − 0.60). Modeling analyses indicated that psychometric reliability breaks down with poorer cognition and more progressed disease stage; split-half reliability was compromised (i.e., split-half reliability < 0.80) when scores were < 136 for Chorea, < 109 for Speech Difficulties, and < 179 for Swallowing Difficulties.

Conclusions

Results indicate that the psychometric reliability of PROs can be compromised as HD symptoms progress and cognition declines. Clinicians should consider PROs in conjunction with other types of assessments when total cognition scores exceed critical thresholds.

Vorheriger Artikel Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study

Nächster Artikel Quality of life among parents seeking treatment for their child’s functional abdominal pain

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

The Huntington’s Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 1993. 72: 971–983.CrossRef

Ross, C. A., et al. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 10(4), 204–216.CrossRefPubMed

Squitieri, F., et al.(2015). Epidemiology of Huntington disease: first post-HTT gene analysis of prevalence in Italy. Clinical Genetics, 89(3), 367–370.

Evans, S. J. W., et al. (2013). Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records. Journal of Neurology Neurosurgery and Psychiatry, 84(10), 1156–1160.CrossRef

Paulsen, J. S. Early Detection of Huntington Disease. Future Neurology, 2010. 5(1), 85–104.CrossRef

Walker, F. O. (2007). Huntington’s disease. Lancet, 369(9557), 218–228.CrossRefPubMed

Ross, C. A., et al. (1997). Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine (Baltimore), 76(5), 305–338.CrossRef

Cella, D. F. (1995). Measuring quality of life in palliative care. Seminars in oncology, 22(2 Suppl 3), 73–81.PubMed

Basch, E. (2010). The missing voice of patients in drug-safety reporting. New England Journal of Medicine, 362(10), 865–869.CrossRefPubMed

10.

Carlozzi, N. E., et al. (2016). HDQLIFE: Development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research, 25(10), 2441–2455.CrossRefPubMedPubMedCentral

11.

Cella, D. F., et al. (2011). The Neurology Quality of Life Measurement (Neuro-QOL) initiative. Archives of Physical Medicine and Rehabilitation, Supplement., 92(Suppl 1), S28-S36.

12.

Cella, D., et al. (2012). Neuro-QOL brief measures of health-related quality of life for clinical research in neurology. Neurology, 78(23), 1860–1867.CrossRefPubMedPubMedCentral

13.

Cella, D. F., et al. (2010). The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested in its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 63, 1179–1194.CrossRefPubMedPubMedCentral

14.

Cella, D. F., et al. (2007). The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Medical Care, 45(5 Suppl 1), S3–S11.

15.

Carlozzi, N. E., et al.(2016). The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Quality of Life Research, 25(20), 2429–2439.

16.

Carlozzi, N. E., et al. (2016). HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Quality of Life Research, 25(10), 2417–2427.

17.

Carlozzi, N. E., et al.(2016). New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Quality of Life Research, 25(10), 2403–2415.

18.

Tabrizi, S. J., et al. (2011). Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, 10(1), 31–42.CrossRefPubMed

19.

Tabrizi, S. J., et al. (2009). Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, 8(9), 791–801.CrossRefPubMedPubMedCentral

20.

Paulsen, J. S., et al. (2014). Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study. Frontiers in Aging Neuroscience, 6, 78.CrossRefPubMedPubMedCentral

21.

Paulsen, J. S., et al. (2001). Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology, 57(4), 658–662.CrossRefPubMed

22.

Peavy, G. M., et al. (2010). Cognitive and functional decline in Huntington’s disease: dementia criteria revisited. Movement Disorders, 25(9), 1163–1169.CrossRefPubMedPubMedCentral

23.

Beglinger, L. J., et al. (2010). Cognitive change in patients with Huntington disease on the repeatable battery for the assessment of neuropsychological status. J Clin Exp Neuropsychol, 32(6), 573–578.CrossRefPubMed

24.

Stout, J. C., et al. (2012). Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington’s disease. Journal of Neurology Neurosurgery Psychiatry, 12(7), 687–694.CrossRef

25.

Williams, J. K., et al. (2015). Everyday cognition in prodromal Huntington disease. Neuropsychology, 29(2), 255–267.CrossRefPubMed

26.

Ward, J., et al. (2006). A four-year prospective study of cognitive functioning in Huntington’s disease. Journal of the International Neuropsychological Society, 12(4), 445–454.CrossRefPubMed

27.

Roos, R. A. (2010). Huntington’s disease: a clinical review. Orphanet Journal of Rare Diseases, 5(1), 40.CrossRefPubMedPubMedCentral

28.

Tabrizi, S. J., et al. (2012). Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, 11(1), 42–53.CrossRefPubMed

29.

Ho, A. K., et al. (2003). Profile of cognitive progression in early Huntington’s disease. Neurology, 61(12), 1702–1706.CrossRefPubMed

30.

Kirkwood, S. C., et al. (2001). Progression of symptoms in the early and middle stages of Huntington disease. Archives of Neurology, 58(2), 273–278.CrossRefPubMed

31.

Cohen, J. (1960). A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 20(1), 10.CrossRef

32.

Paulsen, J. S., et al. (2008). Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery & Psychiatry, 79(8), 874–880.CrossRef

33.

Hanauer, D. A., et al. (2015). Supporting information retrieval from electronic health records: A report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). Journal of Biomedical Informatics, 55, 290–300.CrossRefPubMedPubMedCentral

34.

Jackson, W., & TA, N. (1998). Effective serial measurement of cognitive orientation in rehabilitation: the Orientation Log. Archives of Physical Medicine and Rehabilitation, 79(6), 718–720.CrossRefPubMed

35.

Huntington Study Group, (1996). Unified Huntington’s disease rating scale: Reliability and consistency. Movement Disorders, 11(2): 136–142.CrossRef

36.

Shoulson, I., & Fahn, S. (1979). Huntington disease clinical care and evaluation. Neurology, 29(1), 1–1.CrossRefPubMed

37.

Stroop, J. R. (1992). Studies of interference in serial verbal reactions (Reprinted from Journal Experimental-Psychology, Vol 18, Pg 643–662, 1935). Journal of Experimental Psychology: General, 121(1), 15.CrossRef

38.

Marder, K., et al. (2000). Rate of functional decline in Huntington’s disease. Neurology, 54(2), 452–452.CrossRefPubMed

39.

Smith, A. (1995). Symbol Digit Modalities Test: Manual. Los Angeles: Western Psychological Services.

40.

Crane, P. K., et al. (2006). Differential item functioning analysis with ordinal logistic regression techniques. DIFdetect and difwithpar. Medical Care, 44(11 Suppl 3), S115-S123.

41.

Choi, S. W., Gibbons, L. E., & Crane, P. K. (2011). Lordif: An R package for detecting differential item functioning using iterative hybrid ordinal logistic regression/item response theory and monte carlo simulations. Journal of Statistical Software, 39(8), 1–30.CrossRefPubMedPubMedCentral

42.

Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd edition). New York: Academic Press.

43.

DeVellis, R. (2017) Scale development: Theory and applications. In L. Bickman & D. J. Rog (Eds.) Applied social research methods series, 4th edn. Los Angeles: Sage.

44.

Heemskerk, A. W., & Roos, R. A. (2011). Dysphagia in Huntington’s disease: A review. Dysphagia, 26(1), 62–66.CrossRefPubMed

45.

Kagel, M. C., & Leopold, N. A. (1992). Dysphagia in Huntington’s disease: A 16-year retrospective. Dysphagia, 7(2), 106–114.CrossRefPubMed

46.

Reilmann, R., Leavitt, B. R., & Ross, C. A. (2014). Diagnostic criteria for Huntington’s disease based on natural history. Movement Disorders, 29(11), 1335–1341.CrossRefPubMed

47.

Ross, C. A., et al. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews. Neurology, 10, 204–216.CrossRefPubMed

48.

Dorsey, E. R., et al. (2013). Natural history of Huntington disease. JAMA Neurol, 70(12), 1520–1530.PubMed

49.

Pagan, F., Torres-Yaghi, Y., & Altshuler, M. (2017). The diagnosis and natural history of Huntington disease. Handbook of Clinical Neurology, 144, 63–67.CrossRefPubMed

50.

McCusker, E., & Loy, C. T. (2014). The many facets of unawareness in Huntington disease. Tremor Other Hyperkinet Mov (N Y), 4, 257.

51.

Deckel, A. W., & Morrison, D. (1996). Evidence of a neurologically based “denial of illness” in patients with Huntington’s disease. Archives of Clinical Neuropsychology, 11(4), 295–302.CrossRefPubMed

52.

Vitale, C., et al. (2001). Unawareness of dyskinesias in Parkinson’s and Huntington’s diseases. Neurological Sciences, 22(1), 105–106.CrossRefPubMed

53.

Chatterjee, A., et al. (2005). A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 17(3), 378–383.CrossRefPubMed

54.

Duff, K., et al. (2010). “Frontal” behaviors before the diagnosis of Huntington’s disease and their relationship to markers of disease progression: evidence of early lack of awareness. The Journal of Neuropsychiatry and Clinical Neurosciences, 22(2), 196–207.CrossRefPubMedPubMedCentral

55.

Pringsheim, T., et al. (2012). The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Movement Disorders, 27(9), 1083–1091.CrossRefPubMed

56.

Folstein, S. E..(1989). Huntington’s disease: A disorder of families. Baltimore :Johns Hopkins University Press.

57.

Hayden, M. R., MacGregor, J. M., & Beighton, P. H. (1980). The prevalence of Huntington’s chorea in South Africa. South African Medical Journal, 58, 193–196.PubMed

58.

Narabayashi, H. (1973). Huntington’s chorea in Japan: Review of the literature. Advances in neurology, 1, 253–259.

Titel: Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?
verfasst von: N. E. Carlozzi
S. Schilling
A. L. Kratz
J. S. Paulsen
S. Frank
J. C. Stout
Publikationsdatum: 16.06.2018
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 10/2018
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-018-1912-6

Springer Professional

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 10/2018

Third molar removal and its impact on quality of life: systematic review and meta-analysis

Weak social networks and restless sleep interrelate through depressed mood among elderly

Fatigue in the general population: German normative values of the EORTC QLQ-FA12

Health-related quality of life in coronary heart disease: a systematic review and meta-analysis mapped against the International Classification of Functioning, Disability and Health

Association between quality of life and clinical characteristics in patients with morphea

A population-based analysis of life satisfaction and social support among children of diverse backgrounds in British Columbia, Canada